Pasar al contenido principal

ESTUDIO DE LOS MECANISMOS FISIOPATOLOGICOS QUE CONDUCEN A LA HIPERTROFIA MALADAPTATIVA DEL VENTRICULO DERECHO EN LA HIPERTENSION PULMONAR CRONICA

PI17/00995

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA CLINIC
Centro realización HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF), a double blind, placebo-controlled, randomized clinical trial

  • García-Álvarez, Ana|||0000-0002-1718-2424
  • Blanco, Isabel|||0000-0001-9452-3432
  • García-Lunar, Inés
  • Jordà, Paloma|||0000-0002-9236-1713
  • Rodriguez-Arias, Juan J.
  • Fernández-Friera, Leticia
  • Zegrí-Reiriz, Isabel|||0000-0001-9742-8537
  • Nuche, Jorge
  • Gomez-Bueno, Manuel
  • Prat, Susanna
  • Pujadas, Sandra|||0000-0001-5232-4865
  • Solé González, Eduard|||0000-0002-5727-9925
  • Garcia-Cossio, Maria D.
  • Rivas, Mercedes
  • Torrecilla, Estefanía
  • Pereda, Daniel
  • Sánchez González, Javier|||0000-0003-1427-3870
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Segovia, Javier|||0000-0002-4606-3416
  • Delgado-Jiménez, Juan Francisco|||0000-0002-5401-8324
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
  • Fuster, Valentín
  • Barberà i Mir, Joan Albert|||0000-0003-1469-4990
  • Ibañez, Borja|||0000-0002-5036-254X
Aims: Pulmonary hypertension (PH) associated with left heart disease is an increasingly prevalent problem, orphan of targeted therapies, and related to a poor prognosis, particularly when pre- and post-capillary PH combine. The current study aimed to determine whether treatment with the selective β3 adrenoreceptor agonist mirabegron improves outcomes in patients with combined pre- and post-capillary PH (CpcPH). Methods and results: The β3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure (SPHERE-HF) trial is a multicentre, randomized, parallel, placebo-controlled clinical trial that enrolled stable patients with CpcPH associated with symptomatic heart failure. A total of 80 patients were assigned to receive mirabegron (50 mg daily, titrated till 200 mg daily, n = 39) or placebo (n = 41) for 16 weeks. Of them, 66 patients successfully completed the study protocol and were valid for the main analysis. The primary endpoint was the change in pulmonary vascular resistance (PVR) on right heart catheterization. Secondary outcomes included the change in right ventricular (RV) ejection fraction by cardiac magnetic resonance or computed tomography, other haemodynamic variables, functional class, and quality of life. The trial was negative for the primary outcome (placebo-corrected mean difference of 0.62 Wood units, 95% confidence interval [CI] -0.38, 1.61, p = 0.218). Patients receiving mirabegron presented a significant improvement in RV ejection fraction as compared to placebo (placebo-corrected mean difference of 3.0%, 95% CI 0.4, 5.7%, p = 0.026), without significant differences in other pre-specified secondary outcomes. Conclusions: SPHERE-HF is the first clinical trial to assess the potential benefit of β3 adrenergic agonists in PH. The trial was negative since mirabegron did not reduce PVR, the primary endpoint, in patients with CpcPH. On pre-specified secondary outcomes, a significant improvement in RV ejection fraction assessed by advanced cardiac imaging was found, without differences in functional class or quality of life.